OpGen, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US68373L4068
USD
10.00
1 (11.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.54 k

Shareholding (Sep 2024)

FII

0.21%

Held by 8 FIIs

DII

99.49%

Held by 0 DIIs

Promoter

0.00%

How big is OpGen, Inc.?

22-Jun-2025

As of Jun 18, OpGen, Inc. has a market capitalization of 49.13 million, with net sales of 1.27 million and a net profit of -9.40 million over the last four quarters. Shareholder's funds are -11.56 million, and total assets are 1.88 million.

As of Jun 18, OpGen, Inc. has a market capitalization of 49.13 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 1.27 million, while the sum of net profit for the same period is -9.40 million.<BR><BR>As of Dec 23, the shareholder's funds are reported at -11.56 million, and total assets amount to 1.88 million.

Read More

What does OpGen, Inc. do?

22-Jun-2025

OpGen, Inc. is a precision medicine company specializing in molecular diagnostics and informatics for infectious diseases. As of September 2024, it has a market cap of $49.13 million and reported a net profit of $9 million.

Overview:<BR>OpGen, Inc. is a precision medicine company in the miscellaneous industry, focused on using molecular diagnostics and informatics to combat infectious disease.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: 9 Million (Quarterly Results - Sep 2024)<BR>- Market-cap: USD 49.13 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.43<BR>- Return on Equity: -659.91%<BR>- Price to Book: 16.45<BR><BR>Contact Details:<BR>- Address: 708 Quince Orchard Rd Ste 205, GAITHERSBURG MD: 20878-1793<BR>- Tel: ['1 240 8131260', '1 240 8131273']<BR>- Fax: 1 301 8699684<BR>- Website: http://opgen.com/

Read More

Should I buy, sell or hold OpGen, Inc.?

22-Jun-2025

Who are in the management team of OpGen, Inc.?

22-Jun-2025

As of March 2022, the management team of OpGen, Inc. includes Chairman William Rhodes, CEO Oliver Schacht, and Directors Mario Crovetto, Prabhavathi Fernandes, Evan Jones, and R. Donald Elsey. They oversee the company's strategic direction and operations.

As of March 2022, the management team of OpGen, Inc. includes the following individuals:<BR><BR>- Mr. William Rhodes, Chairman of the Board<BR>- Mr. Oliver Schacht, President, Chief Executive Officer, and Director<BR>- Mr. Mario Crovetto, Director<BR>- Dr. Prabhavathi Fernandes, Director<BR>- Mr. Evan Jones, Director<BR>- Mr. R. Donald Elsey, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is OpGen, Inc. overvalued or undervalued?

20-Sep-2025

As of August 4, 2025, OpGen, Inc. is considered undervalued with an attractive valuation grade despite significant losses and negative returns, presenting a potential investment opportunity compared to worse-performing peers.

As of 4 August 2025, OpGen, Inc. has moved from a fair to attractive valuation grade. The company appears to be undervalued, particularly given its current Price to Book Value of 15.85 and an EV to Capital Employed ratio of 27.07, despite being loss-making and having negative returns on capital and equity. In comparison, peers such as BTC Digital Ltd. and LM Funding America, Inc. exhibit significantly worse valuation metrics, with P/E ratios of -12.06 and -2.15, respectively.<BR><BR>The stock has experienced a staggering decline, with year-to-date returns of -99.98% compared to a 12.22% gain in the S&P 500, indicating a severe underperformance relative to the broader market. This dramatic drop underscores the potential for recovery, suggesting that OpGen, Inc. may present a compelling investment opportunity given its attractive valuation grade amidst a challenging performance backdrop.

Read More

Is OpGen, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, OpGen, Inc. has shifted to a mildly bearish trend, indicated by a bearish MACD and moving averages, despite a bullish weekly RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -99.98%.

As of 11 September 2025, the technical trend for OpGen, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and bearish moving averages on the daily timeframe. The weekly RSI indicates bullish momentum, but the overall trend is dampened by mildly bearish signals from Bollinger Bands and KST. Additionally, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.98% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 0%

  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2

Poor long term growth as Net Sales has grown by an annual rate of 8.24% and Operating profit at 15.29% over the last 5 years

 
3

Positive results in Dec 24

4

With ROE of -659.91%, it has a risky valuation with a 15.85 Price to Book Value

5

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

-5.37%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2024)
Net Profit:
4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9999900.0%
0%
9999900.0%
6 Months
119.78%
0%
119.78%
1 Year
525.0%
0%
525.0%
2 Years
149.94%
0%
149.94%
3 Years
6562.23%
0%
6562.23%
4 Years
624.64%
0%
624.64%
5 Years
407.61%
0%
407.61%

OpGen, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.24%
EBIT Growth (5y)
15.29%
EBIT to Interest (avg)
-8.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
-0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.93%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
15.85
EV to EBIT
-7.71
EV to EBITDA
-8.23
EV to Capital Employed
27.07
EV to Sales
36.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-351.21%
ROE (Latest)
-659.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.3%)

Foreign Institutions

Held by 8 Foreign Institutions (0.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -50.56% vs 656.25% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.50",
          "val2": "-0.70",
          "chgp": "742.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "10.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.40",
          "val2": "8.90",
          "chgp": "-50.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "895.30%",
          "val2": "0.00%",
          "chgp": "89.53%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 30.77% vs -39.53% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 12.33% vs -7.18% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.40",
          "val2": "2.60",
          "chgp": "30.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-20.60",
          "chgp": "30.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "3.30",
          "chgp": "-45.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.00",
          "val2": "-12.20",
          "chgp": "83.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.70",
          "val2": "-37.30",
          "chgp": "12.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,589.50%",
          "val2": "-8,521.80%",
          "chgp": "393.23%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
5.00
0.00
Operating Profit (PBDIT) excl Other Income
4.50
-0.70
742.86%
Interest
0.00
0.00
Exceptional Items
0.00
10.30
-100.00%
Consolidate Net Profit
4.40
8.90
-50.56%
Operating Profit Margin (Excl OI)
895.30%
0.00%
89.53%
USD in Million.
Net Sales

QoQ Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -50.56% vs 656.25% in Sep 2024

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
3.40
2.60
30.77%
Operating Profit (PBDIT) excl Other Income
-14.40
-20.60
30.10%
Interest
1.80
3.30
-45.45%
Exceptional Items
-2.00
-12.20
83.61%
Consolidate Net Profit
-32.70
-37.30
12.33%
Operating Profit Margin (Excl OI)
-4,589.50%
-8,521.80%
393.23%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 30.77% vs -39.53% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 12.33% vs -7.18% in Dec 2022

stock-summaryCompany CV
About OpGen, Inc. stock-summary
stock-summary
OpGen, Inc.
Miscellaneous
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Company Coordinates stock-summary
Company Details
708 Quince Orchard Rd Ste 205 , GAITHERSBURG MD : 20878-1793
stock-summary
Tel: 1 240 81312601 240 8131273
stock-summary
Registrar Details